152 related articles for article (PubMed ID: 27911280)
1. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review.
Guo H; Zhou S; Tan L; Wu X; Wu Z; Ran R
Oncotarget; 2017 Jan; 8(2):2550-2557. PubMed ID: 27911280
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers.
Yoshino M; Suzuki M; Tian L; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Shibuya K; Yoshino I
Int J Oncol; 2009 Nov; 35(5):1201-9. PubMed ID: 19787276
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis.
Zheng Y; Li X; Jiang Y; Xu Y; Song B; Zhou Q; Liang X; Yang X
Medicine (Baltimore); 2016 Dec; 95(49):e5433. PubMed ID: 27930522
[TBL] [Abstract][Full Text] [Related]
4. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
Yang TM; Leu SW; Li JM; Hung MS; Lin CH; Lin YC; Huang TJ; Tsai YH; Yang CT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):919-24. PubMed ID: 19085002
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review.
Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y
Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788
[TBL] [Abstract][Full Text] [Related]
6. Association between Retinoic acid receptor-β hypermethylation and NSCLC risk: a meta-analysis and literature review.
Li Y; Lu DG; Ma YM; Liu H
Oncotarget; 2017 Jan; 8(4):5814-5822. PubMed ID: 28008143
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer.
Tan M; Wu J; Cai Y
Biochem Biophys Res Commun; 2013 Sep; 438(4):673-9. PubMed ID: 23939044
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
Wu X; Wu G; Yao X; Hou G; Jiang F
Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
Yan W; Xu N; Han X; Zhou XM; He B
Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
[TBL] [Abstract][Full Text] [Related]
11. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.
Mazieres J; He B; You L; Xu Z; Lee AY; Mikami I; Reguart N; Rosell R; McCormick F; Jablons DM
Cancer Res; 2004 Jul; 64(14):4717-20. PubMed ID: 15256437
[TBL] [Abstract][Full Text] [Related]
12. Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells.
Gao Z; Xu Z; Hung MS; Lin YC; Wang T; Gong M; Zhi X; Jablon DM; You L
Anticancer Res; 2009 Jun; 29(6):2025-30. PubMed ID: 19528461
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance and potential drug target of T-cadherin in NSCLC.
Wang Z; Wang B; Guo H; Shi G; Hong X
Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
[TBL] [Abstract][Full Text] [Related]
15. WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival.
Lin B; Hong H; Jiang X; Li C; Zhu S; Tang N; Wang X; She F; Chen Y
Gene; 2017 Jul; 622():42-49. PubMed ID: 28438695
[TBL] [Abstract][Full Text] [Related]
16. Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer.
Xie J; Zhang Y; Hu X; Lv R; Xiao D; Jiang L; Bao Q
Med Oncol; 2015 May; 32(5):145. PubMed ID: 25814287
[TBL] [Abstract][Full Text] [Related]
17. Hypomethylation effects of curcumin, demethoxycurcumin and bisdemethoxycurcumin on WIF-1 promoter in non-small cell lung cancer cell lines.
Liu YL; Yang HP; Gong L; Tang CL; Wang HJ
Mol Med Rep; 2011; 4(4):675-9. PubMed ID: 21484077
[TBL] [Abstract][Full Text] [Related]
18. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
19. Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation.
Lee SM; Park JY; Kim DS
Mol Cells; 2013 Jul; 36(1):69-73. PubMed ID: 23686431
[TBL] [Abstract][Full Text] [Related]
20. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
